Hypoxia‐targeting therapy for intestinal T‐cell lymphoma in dogs: Preclinical study using 3D in vitro models

AbstractThe transcription factor hypoxia‐inducible factor 1α (HIF‐1α) is activated in response to oxygen deficiency, and is expressed in several cancers under intratumoral hypoxic stress that arises during pathogenic processes. Hypoxic stimulation enhanced the growth potential of canine lymphoma cells by activating the HIF‐1α signalling pathway in a previously reported study. The aim of this study was to establish a molecular design strategy for a novel hypoxia‐targeting therapy for intestinal T‐cell lymphoma (ITL) in dogs. We assessed the relationship between immunohistochemistry‐based HIF‐1α expression and clinical information, including signalment, tumour area, clinical signs, systemic diseases, treatment protocol, follow‐up information, chemotherapy response and overall survivals (OS), using 48 tissue samples from dogs with ITL. We investigated the effects of hypoxic stimulation on the biological behaviour of cell lines from three different types of canine ITL. We assessed the effects of evofosfamide (Evo; hypoxia‐activated prodrug) on cell lines cultured under hypoxic conditions. Our data showed that treatment response and overall survival might be significantly decreased in dogs with higher HIF‐1α expression than in those with lower HIF‐1α expression. Hypoxic culture (1% O2, 72 h) enhanced the invasiveness of cell lines and decreased their sensitivity to CCNU, resulting in hypoxia‐dependent aggressive behaviour. Sensitivity to Evo significantly increased in cell lines cultured under hypoxia compared with those cultured under normoxia, which exhibited hypoxia‐dependent apoptosis. Additionally, Evo downregulated HIF‐1α expression in cell lines cultured under hypoxia, suggesting that Evo might inhibit cell growth by inactivating HIF‐1α‐dependent cell signalling. Our results revealed the preclinical antitumor activity of Evo and provide a rationale for treatment strategies for dogs with ITL.